Format

Send to

Choose Destination
Curr Oncol. 2015 Dec;22(6):e498-501. doi: 10.3747/co.22.2700.

Does CDKN2A loss predict palbociclib benefit?

Author information

1
National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.;

Abstract

Palbociclib, an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6, was recently approved by the U.S. Food and Drug Administration in combination with letrozole for postmenopausal women with advanced hormone receptor-positive, her2-negative breast cancer. Patients with loss of CDKN2A (p16), an inherent negative regulator of cyclin-dependent kinases 4 and 6, were not separately studied because of the significant response of the patients selected based only on receptor status. Here, we report a patient with metastatic estrogen receptor- positive, her2-negative breast cancer with CDKN2A loss who experienced a clinical response to palbociclib.

KEYWORDS:

Medical oncology; breast cancer

Supplemental Content

Full text links

Icon for Multimed Inc. Icon for PubMed Central
Loading ...
Support Center